Table 3.
Overall survival | Progression-free survival | |||||
---|---|---|---|---|---|---|
Factor | Univariate p-value |
Multivariate p-value |
HR | Univariate p-value |
Multivariate p-value |
HR |
Gender (male vs female) | 0.24 | — | — | 0.34 | — | — |
Age group (<70 vs. ≥70 years) | 0.20 | — | — | 0.49 | — | — |
ECOG (0–1 vs. 2) | <0.001 | 0.008 | 1.96 | 0.002 | 0.011 | 1.78 |
Anemia (absent vs present) | 0.016 | 0.024 | 1.64 | 0.032 | 0.036 | 1.52 |
T-stage (1–2 vs. 3–4) | 0.009 | 0.017 | 1.42 | 0.004 | 0.007 | 1.51 |
N-stage (1 vs. 2–3) | 0.006 | 0.009 | 1.63 | 0.002 | 0.005 | 1.74 |
PIV (<417 vs. ≥ 417) | <0.001 | <0.001 | 3.28 | <0.001 | <0.001 | 2.39 |
HR: hazard ratio; ECOG: eastern cooperative oncology group; T-stage: tumor stage, N-stage: nodal stage; PIV: pan-immune-inflammation value.